secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2026-10-05T11:00:14+00:00
Accession:  0001193125-26-413090
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Alector licenses AL050 GCase program to Genentech for $100M upfront and up to $1.17B milestones
--------------------------------------------------------------------------------

- Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050, a brain-penetrant GCase enzyme replacement therapy.
- Alector receives $100 million upfront and is eligible for up to $1.17 billion in development, regulatory, and commercial milestones plus tiered royalties.
- Alector exercised its Spur option and will pay Spur $15 million plus a teens percentage of Genentech milestone and other non-royalty partnering income.
- Preliminary cash and marketable securities were about $138.7 million as of Sept 30, 2026, or $223.7 million pro forma after Genentech upfront and Spur payment.
- The Genentech deal extends Alector's cash runway into 2029; Alector will host an R&D webinar on Oct 13, 2026 for AL137, AL164, and AL062.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526413090/0001193125-26-413090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526413090/alec-20260930.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-413090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer